KR20240014482A - B 세포 림프종에서 T 세포 재지향 항체에 대한 표적으로서의 Bcma - Google Patents

B 세포 림프종에서 T 세포 재지향 항체에 대한 표적으로서의 Bcma Download PDF

Info

Publication number
KR20240014482A
KR20240014482A KR1020237044376A KR20237044376A KR20240014482A KR 20240014482 A KR20240014482 A KR 20240014482A KR 1020237044376 A KR1020237044376 A KR 1020237044376A KR 20237044376 A KR20237044376 A KR 20237044376A KR 20240014482 A KR20240014482 A KR 20240014482A
Authority
KR
South Korea
Prior art keywords
bcma
ser
val
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237044376A
Other languages
English (en)
Korean (ko)
Inventor
호머 아담스 Iii
랄루카 베로나
아르논 피. 케이터
에릭 프레더릭 엘더링
Original Assignee
얀센 바이오테크 인코포레이티드
아카데미쉬 메디쉬 센트럼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오테크 인코포레이티드, 아카데미쉬 메디쉬 센트럼 filed Critical 얀센 바이오테크 인코포레이티드
Publication of KR20240014482A publication Critical patent/KR20240014482A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020237044376A 2021-05-28 2022-05-26 B 세포 림프종에서 T 세포 재지향 항체에 대한 표적으로서의 Bcma Pending KR20240014482A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163194470P 2021-05-28 2021-05-28
US63/194,470 2021-05-28
US202163209694P 2021-06-11 2021-06-11
US63/209,694 2021-06-11
PCT/EP2022/064362 WO2022248642A1 (en) 2021-05-28 2022-05-26 Bcma as a target for t cell redirecting antibodies in b cell lymphomas

Publications (1)

Publication Number Publication Date
KR20240014482A true KR20240014482A (ko) 2024-02-01

Family

ID=82115891

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044376A Pending KR20240014482A (ko) 2021-05-28 2022-05-26 B 세포 림프종에서 T 세포 재지향 항체에 대한 표적으로서의 Bcma

Country Status (10)

Country Link
US (1) US20220411525A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347039A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024519545A (cg-RX-API-DMAC7.html)
KR (1) KR20240014482A (cg-RX-API-DMAC7.html)
CN (1) CN119679935A (cg-RX-API-DMAC7.html)
AU (1) AU2022281104A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024822A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221399A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014139A (cg-RX-API-DMAC7.html)
WO (1) WO2022248642A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment

Also Published As

Publication number Publication date
BR112023024822A2 (pt) 2024-02-20
WO2022248642A1 (en) 2022-12-01
US20220411525A1 (en) 2022-12-29
CA3221399A1 (en) 2022-12-01
CN119679935A (zh) 2025-03-25
EP4347039A1 (en) 2024-04-10
MX2023014139A (es) 2023-12-13
JP2024519545A (ja) 2024-05-15
AU2022281104A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
US20230119066A1 (en) Anti-ccr8 antibodies for treating cancer
TW202208429A (zh) 用於治療多發性骨髓瘤之方法
KR20190015520A (ko) 조합 치료법
KR20190050816A (ko) Siglec-15를 위한 항체 및 이의 사용 방법
EP4118105A2 (en) Cd80-fc fusion protein and uses thereof
CA3232806A1 (en) B7-h4 antibody-drug conjugates for the treatment of cancer
US20240327544A1 (en) Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
AU2021346129A1 (en) Methods for treating multiple myeloma
WO2024095173A1 (en) Methods of treating cancers
JP2023517794A (ja) 抗tnfr2抗体及びその使用
US20220411525A1 (en) Bcma as a target for t cell redirecting antibodies in b cell lymphomas
CA3087968A1 (en) Anti-siglec-7 antibodies having reduced effector function
WO2023010483A1 (en) Anti-human cxcr5 antibody and uses thereof
CA3168173A1 (en) Anti-gitr antibodies and uses thereof
US20240158517A1 (en) Anti-human cxcr5 antibody and uses thereof
CN118043070A (zh) Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标
JP2021105053A (ja) Pd−1/cd3二重特異性タンパク質による血液がん治療
HK40110611A (en) Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
HK40103924A (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies
EA052230B1 (ru) Мультиспецифические связывающие агенты против cd40 и cd137 в комбинированной терапии
CN117957253A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
EA050839B1 (ru) Способы лечения множественной миеломы
CA3124168A1 (en) Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
HK40092079A (en) Anti-tnfr2 antibody and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231221

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20240912

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D